ArticleFrontiers in medicine2026
Case Report: Severe persistent transaminitis during pregnancy: a complex differential diagnosis involving suspected toxoplasmosis, possible drug-induced liver injury, and intrahepatic cholestasis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe transaminitis during pregnancy represents a diagnostic challenge because multiple etiologies may coexist. We report a pregnant woman with suspected toxoplasmosis, intrahepatic cholestasis of pregnancy, and possible drug-induced liver injury who developed prolonged severe liver dysfunction despite extensive investigation and treatment. Case presentation: A 33-year-old primigravida was referred at 15 weeks' gestation because of positive Toxoplasma gondii serology and elevated liver enzymes (ALT/AST 460/150 U/L). Despite treatment with spiramycin, later changed to pyrimethamine-based therapy, and ursodeoxycholic acid, liver injury progressed (ALT/AST 1,363/466 U/L). Amniocentesis at 25 weeks showed negative T. gondii PCR. At 27 weeks, liver injury peaked (ALT/AST 1,734/728 U/L); anti-SS-A/Ro52 antibodies were detected, and bile acids subsequently increased to 82.4 μmol/L. Extensive investigations excluded viral hepatitis and did not support autoimmune hepatitis, while serial fetal assessment and amniotic fluid PCR showed no evidence of congenital toxoplasmosis. The clinical picture was considered most consistent with multifactorial liver injury involving possible drug-induced hepatotoxicity and intrahepatic cholestasis of pregnancy in the setting of suspected toxoplasmosis. Labor was induced at 38 weeks. A healthy male infant (3,140 g, Apgar scores 10/10) was delivered vaginally. Three days postpartum, ALT/AST decreased to 90/57 U/L. Conclusion: Severe transaminitis during pregnancy may have a multifactorial etiology, particularly when infectious, pregnancy-specific, medication-related, and immunological findings coexist. This case highlights the importance of careful differential diagnosis and multidisciplinary management when severe hepatocellular injury develops during pregnancy. Close maternal and fetal surveillance enabled the continuation of pregnancy to term, resulting in favorable maternal and neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.